SEQUENCE LISTING

```
<110> Auf der Maur, Adrian
      Barberis, Alcide
      Escher, Dominik
<120> INTRABODIES WITH DEFINED FRAMEWORK THAT IS STABLE IN A
      REDUCING ENVIRONMENT AND APPLICATIONS THEREOF
<130> 27656/37021
<140>
<141>
<150> 09/529,307
<151> 2000-04-11
<150> PCT/IB00/00218
<151> 2000-03-01
<150> PCT/IB99/02054
<151> 1999-12-28
<160> 11
<170> PatentIn Ver. 2.1
<210> 1
<211> 252
<212> PRT
<213> Mus musculus
<220>
<221> CHAIN
<222> (1)..(114)
<223> Variable light chain
<220>
<221> CHAIN
<222> (135)..(247)
<223> Variable heavy chain
<220>
<221> REPEAT
<222> (115)..(134)
<223> Glycine Serine Linker
<220>
<221> PEPTIDE
<222> (248)..(252)
<223> His Tag
<220>
```

<221> DOMAIN

```
<222> (27)..(39)
<223> CDR 1 VL
```

<220>

<221> DOMAIN

<222> (95)..(103)

<223> CDR 3 VL

<220>

<221> DOMAIN

<222> (165)..(169)

<223> CDR 1 VH

<220>

<221> DOMAIN

<222> (184)..(198)

<223> CDR 2 H

<220>

<221> DOMAIN

<222> (232)..(236)

<223> CDR 3 VH

<400> 1

Met Gly Pro Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala 1 5 10 15

Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala
20 25 30

Val Thr Thr Ser Asn Tyr Ala Ser Trp Val Gln Lys Lys Pro Gly Lys
35 40 45

Arg Phe Lys Gly Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val
50 60

Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr 65 70 75 80

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Ala Leu 85 90 95

Trp Tyr Ser Asn His Trp Val Phe Gly Gln Gly Thr Lys Val Glu Leu 100 105 110

Lys Arg Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 115 120 125

Ser Ser Gly Gly Ser Glu Val Lys Leu Leu Glu Ser Gly Gly Gly 130 135 140

Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Val Ser Gly
145 150 155 160

Phe Ser Leu Thr Asp Tyr Gly Val Asn Trp Val Arg Gln Ala Pro Gly 175

Arg Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Asp Gly Ile Thr Asp 180

Tyr Asn Ser Ala Leu Lys Asp Arg Phe Ile Ile Ser Lys Asp Asp Cys 205

Glu Asn Ser Val Tyr Leu Gln Met Ser Lys Val Arg Ser Asp Asp Thr 210 215 220

Ala Leu Tyr Tyr Cys Val Thr Gly Leu Phe Asp Tyr Trp Gly Gln Gly 225 230 235 240

Thr Leu Val Thr Val Ser Ser His His His His 250

<210> 2 <211> 5 <212> PRT <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
 peptide

<400> 2 Gly Leu Phe Asp Tyr 1 5

<210> 3

<211> 6 <212> PRT <213> Artificial Sequence

<223> Description of Artificial Sequence: synthetic peptide


<400> 3 Ala Gly Leu Phe Asp Tyr 1 5

<210> 4 <211> 20 <212> PRT <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
 peptide Glycine Serine Linker

```
<400> 4
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser
Gly Gly Gly Ser
<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR upstream
     Primer
<400> 5
ccatgggccc aagctttgca aagatggata aag
                                                                  33
<210> 6
<211> 85
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: synthetic
     peptide linker
<400> 6
tttgggcccg aagaaccgcc accaccagaa ccgcctccac cagagccacc accaccaggc 60
ctgatctctt tttttgggtt tggtg
                                                                  85
<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: synthetic
     peptide linker
<400> 7
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser
<210> 8
<211> 34
<212> DNA
<213> Artificial Sequence
<220>
```

<223> Description of Artificial Sequence: PCR upstream



4